A VEGFR1 antagonistic peptide inhibits tumor growth and metastasis through VEGFR1-PI3K-AKT signaling pathway inhibition

American Journal of Cancer Research

Volumn 5, Issue 10, 2015, Pages 3149-3161

  Zhou, Zheng ^a   Zhao, Chuanke ^a   Wang, Lixin ^a   Cao, Xiaodan ^b   Li, Jian ^b   Huang, Ruijing ^a   Lao, Qiaocong ^b   Yu, Hangping ^c   Li, Yanna ^d,e   Du, Haiyan ^d   Qu, Like ^a   Shou, Chengchao ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b Division of Nutraceutical Products Tasly Holding Group   (China)

^c Hunter Biotechnology Corporation   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e BEIJING INSTITUTE OF HEART   (China)

Author keywords

Angiogenesis; Endothelial cells; Metastasis; Peptide; PI3K Akt; VEGFR1

Indexed keywords

CYCLOPHOSPHAMIDE; F 56; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHICKEN; CHORIOALLANTOIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; EMBRYO; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LUNG METASTASIS; MALE; MELANOMA CELL; MELANOMA METASTASIS; METASTASIS INHIBITION; MIGRATION INHIBITION; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; ZEBRA FISH;

EID: 85006208124     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Potente M, Gerhardt H and Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011; 146: 873-887.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-936.
3. Folkman J and Kalluri R. Cancer without disease. Nature 2004; 427: 787.
4. Sumpio BE, Riley JT and Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol 2002; 34: 1508-1512.
5. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, Mc- Crae KR, Hug BA, Schmidt AM and Stern DM. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-3561.
6. Saharinen P and Alitalo K. The yin, the yang, and the angiopoietin-1. J Clin Invest 2011; 121: 2157-2159.
7. Sulpice E, Ding S, Muscatelli-Groux B, Berge M, Han ZC, Plouet J, Tobelem G and Merkulova- Rainon T. Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biol Cell 2009; 101: 525-539.
8. Cross MJ and Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001; 22: 201-207.
9. Ruhrberg C. Growing and shaping the vascular tree: multiple roles for VEGF. Bioessays 2003; 25: 1052-1060.
10. Shibuya M and Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006; 312: 549-560.
11. Vieira JM, Ruhrberg C and Schwarz Q. VEGF receptor signaling in vertebrate development. Organogenesis 2010; 6: 97-106.
12. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006; 39: 469-478.
13. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt- 1). Int J Biochem Cell Biol 2001; 33: 409-420.
14. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 2006; 9: 225- 230.
15. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S and Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820-827.
16. Koch S, Tugues S, Li X, Gualandi L and Claesson- Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011; 437: 169-183.
17. Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J, Cutillas PR, Smith AJ, Ridley AJ, Ruhrberg C, Gerhardt H and Vanhaesebroeck B. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008; 453: 662-666.
18. An P, Lei H, Zhang J, Song S, He L, Jin G, Liu X, Wu J, Meng L, Liu M and Shou C. Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library. Int J Cancer 2004; 111: 165- 173.
19. Xu QH, Shi JY, Zhang J, Sun YF, Chang AH, Zhao YM, Cai WJ, Liu D, Zhou CC, Fan LH and Su B. Comparison of tumor neovasculature-targeted paramagnetic nanoliposomes for MRI in mice xenograft models. Clin Transl Oncol 2014; 16: 395-401.
20. Herringson TP and Altin JG. Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature. Int J Pharm 2011; 411: 206-214.
21. Brunel FM, Lewis JD, Destito G, Steinmetz NF, Manchester M, Stuhlmann H and Dawson PE. Hydrazone ligation strategy to assemble multifunctional viral nanoparticles for cell imaging and tumor targeting. Nano Lett 2010; 10: 1093-1097.
22. Wang C, Zhao M, Liu YR, Luan X, Guan YY, Lu Q, Yu DH, Bai F, Chen HZ and Fang C. Suppression of colorectal cancer subcutaneous xenograft and experimental lung metastasis using nanoparticle-mediated drug delivery to tumorA peptide inhibits tumor growth and metastasis 3161 Am J Cancer Res 2015;5(10):3149-3161 neovasculature. Biomaterials 2014; 35: 1215- 1226.
23. Baudin B, Bruneel A, Bosselut N and Vaubourdolle M. A protocol for isolation and culture of human umbilical vein endothelial cells. Nat Protocols 2007; 2: 481-485.
24. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
25. Nicosia RF and Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 1990; 63: 115-122.
26. Liekens S, De Clercq E and Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61: 253-270.
27. Ribatti D. The chick embryo chorioallantoic membrane as a model for tumor biology. Exp Cell Res 2014; 328: 314-324.
28. Cimpean AM, Ribatti D and Raica M. Te chick embryo chorioallantoic membrane as a model to study tumor metastasis. Angiogenesis 2008; 11: 311-319.
29. Rubinstein AL. Zebrafish: from disease modeling to drug discovery. Curr Opin Drug Discov Devel 2003; 6: 218-223.
30. Hanahan D and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
31. Baeriswyl V and Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol 2009; 19: 329-337.
32. Bergers G and Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-410.
33. Brazil DP, Park J and Hemmings BA. PKB binding proteins. Getting in on the Akt. Cell 2002; 111: 293-303.
34. Abid MR, Guo S, Minami T, Spokes KC, Ueki K, Skurk C, Walsh K and Aird WC. Vascular endothelial growth factor activates PI3K/Akt/forkheadsignaling in endothelial cells. Arterioscler Thromb Vasc Biol 2004; 24: 294-300.
35. Shiojima I and Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 2002; 90: 1243-1250.